1 We have given fifteen healthy volunteers single doses of racemic (+)-propranolol orally (40 mg) and intravenously (5-10 mg) to find out how large the variation was of the ratio between (-)and (+)-propranlol plasma levels in relation to that of total levels of propranolol and 4-hydroxypropranolol. 2 Total propranolol (+)-levels 2 h after a 40 mg oral dose of (+)-propranolol varied from 21 to 580 nmol/l and those of4-hydroxypropranolol from 0 to 33 nmol/l. Their levels did not correlate. The ratio between (-)and (+)-propranolol levels varied from 0.99 to 2.04. The plasma half-lives of the two isomers were usually similar. 3 We conclude that in most single doses studies on relationships between plasma concentrations and effects (,8-adrenoceptor blockade) it is not necessary to quantitate (+)and (-)-propranolol levels separately since total (+) plasma propranolol levels varied much more than the ratio between (-)and (+)-propranolol.
Introduction
Commercial propranolol is a racemic mixture of two optical isomers, dextro (+)and laevo (-)propranolol. The (-)isomer is more potent than the (+ )-isomer and is responsible for almost all /8adrenoceptor blocking effect (Barrett & Cullum, 1968) . After administration of racemic propranolol (+ -propranolol) to animals the isomers have different disposition kinetics (Kawashima et al., 1976; Levy et al., 1976; Caccia et al., 1979; Walle & Walle, 1979) . Recently we developed a HPLC-method enabling separation and simultaneous quantitation of (+) and (-)-propranolol and found that the isomers had different plasma disposition kinetics in man after giving the racemate (Hermansson & von Bahr, 1980) . The kinetics differed with regard to stereoselectivity from dog (Walle & Walle, 1979) . Differential kinetics of isomers may be important clinically and in studies on plasma concentration-effect relationships.
The aim of this study was to find out how large was the variation of the ratio between (+)and (-)propranolol plasma levels in relation to that of total levels of propranolol and 4-hydroxypropranolol (active metabolite, Fitzgerald & O'Donnell, 1971) under various conditions. By this we should be able to decide how important it is to measure (+)and (-)-0306-5251/82/070079-04 $01.00 propranolol separately in experimental studies. To reach this goal we gave volunteers single doses of racemic propranolol orally and intravenously and measured plasma levels of (+)and (-)-propranolol after 2 h. In some individuals repeated plasma samples were taken to find out if time changed the ratio between plasma levels of (+)and (-)propranolol.
Method

Subjects
Fifteen informed healthy volunteers (aged 23 to 37 years) consented to take part in the study, which was approved by the ethical committee of the hospital. They fasted from midnight the day before the experiment until 2.5 h after dose intake.
Experimental procedure
The subjects arrived fasting in the morning and received one tablet of 40 mg propranolol (Inderal) at 08.00 h.
Blood samples (10-20 ml) were drawn at 2 h after dose. Three subjects repeated the experiment with extended plasma sampling at 0.5, 1, 1.5, 2, 3, 4, 6 and 8 h after an oral dose (40 mg) and 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2.3, 4 and 6 h after an intravenous dose (5 mg) to obtain complete plasma concentration time curves. Between sampling the subjects participated in their ordinary daily activities.
Blood sampling and analytical methods
Blood samples were drawn into heparinized vacuum tubes (Venoject) and were then immediately centrifuged. The plasma was stored frozen at -20°C until. In contrast to Vacutainer tubes (Cotham & Shand, 1975 ) Venoject tubes do not interfere with the distribution of propranolol between blood compartments (Borga, personal communication). Propranolol and 4-hydroxypropranolol were analysed by h.p.l.c. methods (Hermansson, 1982; von Bahr etal., 1982) . Sodium disulphite was added to the plasma to prevent oxidation of 4-hydroxypropranolol (Taburet etal., 1979) .
Results Figure 1 illustrates the change with time in plasma levels of (+)and (-)-propranolol after both oral and intravenous doses in three individuals. The half lives of the isomers were mostly similar. The ratio between (-)and (+)-propranolol plasma levels was highest after oral administration in all these individuals. The plasma levels of propranolol and 4-hydroxypropranolol obtained two hours after intake of a 40 mg propranolol tablet (racemic) are shown in Table 1 . There was a marked variation between individuals in total concentration of propranolol. The ratio between (-)and (+)-propranolol plasma levels ranged from 0.99 to 2.04. The plasma levels of (-)-propranolol almost always exceeded those of (+)-propranolol. The concentration of 4-hydroxypropranolol also varied markedly but it was always considerably lower than that of propranolol. Plasma levels of propranolol and 4-hydroxypropranolol did not correlate. In one individual (No 15) the propranolol concentration was unusually high. No 4-hydroxypropranolol could be detected in her plasma.
Discussion
The plasma concentrations of propranolol and its active metabolite 4-hydroxypropranolol varied extensively between subjects. The ratio between plasma levels of (-)and (+)-propranolol varied much less (twofold). Thus in single dose experimental studies on concentration-effect (/3-adrenoceptor blockade) relationships it seems not necessary to quantitate the (+)and (-)-propranolol separately. The above statement is not with certainty true for ,8-blockers for which the optical isomers have qualitatively different pharmacodynamic effects in various effector organs. For alprenolol we found that one subject had about ten times higher levels of (-)than of (+)-alprenolol Ratio between plasma level of (-)-and (+)-propranolol. nm = not measured; nd = not detectable . In such a situation separate quantitation of the isomers may be important, especially if one takes active metabolites into consideration in the calculations of concentrationeffect relationships.
(-)-propranolol mostly reached higher plasma concentration than (+ )-propranolol confirming data from studies with a limited number of subjects (Hermansson & von Bahr, 1980; Silber & Riegelman, 1980) . The finding is consistent with our data on in vitro metabolism of propranolol with human liver microsomes showing that the cytochrome P450 system oxidizes (+)-propranolol faster than (-)-propranolol . Our data indicate that a stereoselective presystemic clearance of propranolol causes the differential kinetics of the isomers. The present study confirms that the half-lives of (+)and (-)-propranolol are usually similar after giving racemic propranolol (Hermansson & von Bahr, 1980) . This is in line with theories on hepatic elimination of 'high clearance' drugs (Wilkinson & Shand, 1975) . George et al. (1972) found in man that the half-life of (+)-propranolol was shorter than that of (-)propranolol when the isomers were given separately. This may be a result of the reduced hepatic blood flow caused by (-)but not (+)-propranolol (Nies et al., 1973) . Decreased hepatic blood flow should prolong the half-life of a 'high clearance' drug like pro-pranolol. Our data and those of George et al. (1972) are not inconsistent since after administration of the racemate the clearance of both (+)and (-)propranolol would be affected by the decreased liver blood flow caused by (-)-propranolol. However, if only (+)-propranolol is given, the liver blood flow should not be decreased and thus the plasma half-life would be shorter.
One subject had considerably lower plasma clearance of propranolol than the others after intravenous administration. She also had much higher plasma concentration after oral administration and, interestingly, had no detectable plasma levels of 4-hydroxypropranolol. This may indicate that she has a lower capacity to 4-hydroxylate propranolol, a phenomenom which has been described for the antihypertensive drug debrisoquine (Mahgoub et al., 1977) . We have recently found that individuals with unusually high levels of the /3-adrenoceptor blockers, alprenolol, metoprolol and timolol, were slow hydroxylators of debrisoquine (Alvan et al., 1982) . The expert technical assistance by Margareta Lind is acknowledged. The study was supported by grants from the Loo and Hans Osterman's fund, the Swedish National Association against Chest and Heart Diseases and the Swedish Medical Research Council (04X-03902 and 14X-05677). 81 
